The Innovative Medicines Initiative (IMI) has now launched ith 18th and 19th Calls for proposal under IMI2. The call gives researchers from diverse sectors the opportinity to participate in ambitious public - private partnerships that will pave the way for the development of the medicines of the future.
https://www.imi.europa.eu/news-events/newsletter/91st-edition-june-2019#3
IMI2 - Call 18 was launched on 26 June 2019, having deadline for short proposals 26 September 2019 and is a standard, two - stage Call for proposal. It includes the following topics:
· Central repository of digital pathology slides to support the development of artificial intelligence tools
· Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes
· Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project
· Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials
· Accelerating research & innovation for advanced therapy medicinal products
· Supporting the development of engineered T cells
On 26 June, IMI also launched IMI2 – Call 19, which is a single stage restricted Call for proposals. It is designed to support further research activities to allow existing successful IMI consortia to build on the achievements of their initial action, move onto the next step of the research challenge, and maximise the impacts of the initial action results. As such the Call is restricted to the initial consortia of actions that fulfil the following two conditions:
- funded through topics launched under Calls for proposals in 2014 and of 2015, since only these actions are sufficiently advanced in their implementation to be considered for followup research activities;
- derived from topics where the topic text already informed potential applicants about the possibility of a later restricted Call.
In practice, the consortia that meet these criteria are: ADAPT-SMART, BEAt-DKD, DO-IT, HARMONY, INNODIA, ITCC-P4, MOPEAD, NGN-PET, PRISM, RADAR-CNS, RESCEU, RHAPSODY, TransQST.
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2020. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.